“Smoking Cessation and Nicotine Addiction Therapies such as CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001 and others”
The Smoking Cessation and Nicotine Addiction Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Smoking Cessation and Nicotine Addiction Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s ‘Smoking Cessation and Nicotine Addiction Market Insights, Epidemiology, and Market Forecast–2034’ report delivers an in-depth understanding of the Smoking Cessation and Nicotine Addiction historical and forecasted epidemiology as well as the Smoking Cessation and Nicotine Addiction Market Trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Unlock detailed insights into the Smoking Cessation and Nicotine Addiction Market by downloading the comprehensive report from DelveInsight @ Smoking Cessation and Nicotine Addiction Therapeutics Market
Key Takeaways from the Smoking Cessation and Nicotine Addiction Market Report
- The Smoking Cessation and Nicotine Addiction Market Size in the 7MM will increase at a significant CAGR due to increasing prevalent cases of the disease and the launch of the emerging therapies.
- According to DelveInsight estimates, EU4 and the UK accounted for approximately 63,953 thousand cases, which was the highest prevalent cases of tobacco use, followed by the US with around 50,886 thousand cases, and Japan with around 20,185 thousand cases in 2023. These cases are expected to decrease in the US, EU4 the UK, and Japan by 2034.
- Among the EU4 and the UK, Germany had the highest prevalent cases of tobacco use (approximately 18,101 thousand cases), followed by France (approximately 16,429 thousand cases) in 2023. On the other hand, the UK (8,788 thousand cases) had the lowest prevalent cases of tobacco use in EU4 and the UK countries and the 7MM.
- Tobacco use has been identified as male-dominant; in our analysis, the number of males suffering was higher than females. In 2023, ~59% of prevalent cases tobacco use of were of males, while ~41% of cases were of females in the 7MM
- The leading Smoking Cessation and Nicotine Addiction Companies such as Achieve Life Sciences, NFL Biosciences SAS, and others.
- Promising Smoking Cessation and Nicotine Addiction Therapies such as CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, and others.
Gain a competitive edge in the Smoking Cessation and Nicotine Addiction Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Smoking Cessation and Nicotine Addiction Treatment Drugs
Smoking Cessation and Nicotine Addiction Treatment Market
Effective treatment for smoking cessation and nicotine addiction involves a multifaceted approach combining pharmacotherapy, behavioral therapy, and support systems. Pharmacotherapeutic options include nicotine replacement therapies (NRTs) like patches, gums, and lozenges, which help reduce withdrawal symptoms and cravings by delivering controlled doses of nicotine. Medications such as varenicline and bupropion act on neural pathways to diminish the pleasure derived from smoking and alleviate withdrawal effects. Behavioral therapies, including cognitive-behavioral therapy (CBT) and motivational interviewing, address the psychological aspects of addiction by helping individuals develop coping strategies, set goals, and enhance motivation to quit. Support systems, such as counseling, support groups, and helplines, provide continuous encouragement and resources, significantly improving quit rates. Combining these treatments increases the likelihood of successful smoking cessation by addressing both the physiological and psychological components of nicotine addiction.
Smoking Cessation and Nicotine Addiction Market Outlook
There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. Several distinct products and services are available today for smoking cessation, alongside smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapies (NRTs) in the form of transdermal patches, gums, nasal sprays, oral inhalers, and lozenges.
Smoking Cessation and Nicotine Addiction Marketed Drugs
- CHANTIX/ CHAMTIX (varenicline): Pfizer
- ZYBAN (bupropion): GlaxoSmithKline
Discover key developments and opportunities in the Smoking Cessation and Nicotine Addiction Market. Click here to learn more from DelveInsight’s latest report @ Smoking Cessation and Nicotine Addiction Market Size
Smoking Cessation and Nicotine Addiction Emerging Drugs
- Cytisinicline (cytisine): Achieve Life Sciences
- NFL-101: NFL Biosciences SAS
- EMB-001: Embera NeuroTherapeutics, Inc.
Smoking Cessation and Nicotine Addiction Market Dynamics
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, etc., are developing therapies for the treatment of Smoking Cessation and Nicotine Addiction.
Download DelveInsight’s Smoking Cessation and Nicotine Addiction Market report today and stay ahead in this rapidly evolving field. @ Smoking Cessation and Nicotine Addiction Clinical Trials
Scope of the Smoking Cessation and Nicotine Addiction Market Report
- Coverage- 7MM
- Smoking Cessation and Nicotine Addiction Companies- Achieve Life Sciences, NFL Biosciences SAS, and others.
- Smoking Cessation and Nicotine Addiction Therapies- CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, and others.
- Smoking Cessation and Nicotine Addiction Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Smoking Cessation and Nicotine Addiction Unmet Needs, KOL’s views, Analyst’s views, Smoking Cessation and Nicotine Addiction Market Access and Reimbursement
Download the report to understand which factors are driving Smoking Cessation and Nicotine Addiction Market Trends @ Smoking Cessation and Nicotine Addiction Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Smoking Cessation and Nicotine Addiction Market Overview at a Glance
4 Epidemiology and Market Forecast Methodology
5 Key Events
6 Executive Summary of Smoking Cessation and Nicotine Addiction
7 Smoking Cessation and Nicotine Addiction: Disease Background and Overview
8 Epidemiology and Patient Population of Smoking Cessation and Nicotine Addiction
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 Smoking Cessation and Nicotine Addiction: Seven Major Market Analysis
13. Market Size of Smoking Cessation and Nicotine Addiction in Japan
14 Key Opinion Leaders’ View
15 SWOT Analysis
16 Unmet needs
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Smoking Cessation and Nicotine Addiction Market Size in the 7MM was ~USD 2,300 Million in 2023, estimated DelveInsight